The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...